Abstract:Immune checkpoints are crucial molecules for the maintenance of antitumor immune responses. The activation or inhibition of these molecules is dependent on the interactions between receptors and ligands; such interactions can provide inhibitory or stimulatory signals to the various components of the immune system. Over the last 10 years, the inhibition of immune checkpoints, such as cytotoxic T lymphocyte antigen-4, programmed cell death-1, and programmed cell death ligand-1, has taken a leading role in immune therapy. This relatively recent therapy regime is based on the use of checkpoint inhibitors, which enhance the immune response towards various forms of cancer. For a subset of patients with specific forms of cancer, these inhibitors can induce a durable response to therapy; however, the medium response rate to such therapy remains relatively poor. Recent research activities have demonstrated that the disease response to this highly promising therapy resembles the response of many forms of cancer to chemotherapy, where an encouraging initial response is followed by acquired resistance to treatment and progress of the disease. That said, these inhibitors are now used as single agents or in combination with chemotherapies as first or second lines of treatment for about 50 types of cancer. The prevailing opinion regarding immune therapy suggests that for this approach of therapy to deliver on its promise, a number of challenges have to be circumvented. These challenges include understanding the resistance mechanisms to immune checkpoint blockade, the identification of more efficient inhibitors, extending their therapeutic benefits to a wider audience of cancer patients, better management of immune-related adverse side effects, and, more urgently the identification of biomarkers, which would help treating oncologists in the identification of patients who are likely to respond positively to the immune therapies and, last but not least, the prices of therapy which can be afforded by the highest number of patients. Numerous studies have demonstrated that understanding the interaction between these checkpoints and the immune system is essential for the development of efficient checkpoint inhibitors and improved immune therapies. In the present text, we discuss some of these checkpoints, their inhibitors, and some works in which mass spectrometry-based proteomic analyses were applied.

Immune Checkpoint molecules in solid organ transplantation: a promising way to prevent rejection

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

PD-1/PD-L1, PD-1/PD-L2, and Other Co-Inhibitory Signaling Pathways in Transplantation

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Rethinking Immune Check Point Inhibitors Use in Liver Transplantation: Implications and Resistance

Tumor Immune Checkpoints and Their Associated Inhibitors

Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients

Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions

Immune rejection: current understanding and new solutions

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Immune Checkpoints as Therapeutic Targets in Autoimmunity

Non‐invasive molecular biomarkers for monitoring solid organ transplantation: A comprehensive overview

Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Proteomic Investigation of Immune Checkpoints and Some of Their Inhibitors

Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective

Immunopathology of lung transplantation: from infection to rejection and vice versa

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy

Innate immune modulation in transplantation: mechanisms, challenges, and opportunities